Patents Examined by Elizabeth A Shupe
-
Patent number: 12269883Abstract: The present invention provides binding agents that specifically bind to CD8+KIR+ T regulatory cells and their use in the treatment of diseases or disorders, such as an inflammatory disease, an autoimmune disease, cancer, or an infectious disease.Type: GrantFiled: October 4, 2024Date of Patent: April 8, 2025Assignee: Mozart Therapeutics, IncInventors: Courtney Crane, Kristine Swiderek, Susan Julien
-
Patent number: 12269887Abstract: An anti-canine CD16 polypeptide generally includes a CDR region of SEQ ID NO:5, a CDR region of SEQ ID NO:9, or a functional variant of either CDR region. An anti-canine CD64 polypeptide generally includes a CDR region of SEQ ID NO:13, a CDR region of SEQ ID NO:17, or a functional variant of either CDR region. The anti-canine CD16 polypeptide and anti-canine CD64 polypeptide may be incorporated into a therapeutic compound, a multispecific compound, a targeted imaging compound, or a capture assay device.Type: GrantFiled: January 20, 2023Date of Patent: April 8, 2025Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTAInventors: Bruce K. Walcheck, Jianming Wu, Daniel A. Vallera
-
Patent number: 12264191Abstract: The present invention relates to the field of therapeutic proteins, in particular, to recombinant coagulation factors. It provides a recombinant Factor VIII (FVIII) protein comprising specific point mutations at defined positions, which serve to reduce the immunogenicity of said FVIII protein, wherein the Factor VIII protein substantially retains its coagulant activity. It further provides nucleic acids encoding said de-immunized protein, cell lines and methods of recombinant preparation as well as pharmaceutical compositions comprising the recombinant FVIII of the invention, which are advantageous for use in treatment of patients with Hemophilia A, particularly those who have not yet been treated with a FVIII product. Additionally, it can be a safe alternative for previously treated patients and even for patients who have developed an immune-response to FVIII, e.g., for immune-tolerance-induction therapy (ITI/ITT) or rescue ITI.Type: GrantFiled: April 11, 2019Date of Patent: April 1, 2025Assignee: Biotest AGInventors: Karina Winterling, Steffen Kistner, Jens Daufenbach, Annie de Groot, William Martin, Christopher Ungerer
-
Patent number: 12263234Abstract: Provided are anti-PD-L1 diabodies, imaging agents, methods and kits for determination of the distribution and expression levels of PD-L1 in an individual having a disease or condition. Anti-PD-L1 diabody agents, and methods for treating diseases or disorders are also provided.Type: GrantFiled: January 17, 2020Date of Patent: April 1, 2025Assignee: Tayu Huaxia Biotech Medical Group Co., Ltd.Inventors: Lieping Chen, Zhenguo Wen, Liqun Luo, Qianyong Liu
-
Patent number: 12264197Abstract: Anti-V?17/anti-CD123 bispecific antibodies or antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies.Type: GrantFiled: March 11, 2020Date of Patent: April 1, 2025Assignee: JANSSEN BIOTECH, INC.Inventors: Rajkumar Ganesan, Iqbal S. Grewal, Manuel Alejandro Sepulveda
-
Patent number: 12258413Abstract: The present invention relates to a bispecific antibody in which an N-terminal side polypeptide is bound to an IgG portion that binds to TfR, a bispecific antibody fragment thereof, a DNA encoding the bispecific antibody or the bispecific antibody fragment thereof, a vector containing the DNA, a hybridoma and a transformant that produce the bispecific antibody or the bispecific antibody fragment thereof, a method for producing the bispecific antibody or the bispecific antibody fragment thereof, therapeutic and diagnostic agents containing the bispecific antibody or the bispecific antibody fragment thereof, therapeutic and diagnostic methods using the bispecific antibody or the bispecific antibody fragment thereof, and a reagent for detection or measurement containing the bispecific antibody or the bispecific antibody fragment thereof.Type: GrantFiled: December 27, 2019Date of Patent: March 25, 2025Assignee: KYOWA KIRIN CO., LTD.Inventors: Keisuke Mitamura, Ryosuke Nakano, Masayuki Kai, Nobuaki Takahashi
-
Patent number: 12240905Abstract: Disclosed are isolated monoclonal antibodies, comprising a CD152-binding domain, wherein the antibodies bind specifically to human CD152. Methods of making and using the antibodies to treat diseases including cancers and autoimmune diseases are also provided.Type: GrantFiled: July 14, 2021Date of Patent: March 4, 2025Assignee: Harbour BioMed (Shanghai) Co., Ltd.Inventors: Xin Gan, Yun He, Yuqiang Shen, Jiuqiao Zhao, Yiping Rong, Frank Grosveld, Dubravka Drabek, Marinus (Rien) Van Haperen, Rick Janssens
-
Patent number: 12195553Abstract: Disclosed are the development of a recombinant chicken IgY monoclonal antibody and a recombinant chicken IgY single-chain variable fragment (scFv) antibody raised against human thymidine kinase 1 in mammalian cells and a preparation method and use thereof. A light chain of the scFv antibody includes an amino acid sequence shown in SEQ ID NO: 1, and a heavy chain of the scFv antibody includes an amino acid sequence shown in SEQ ID NO: 2.Type: GrantFiled: March 4, 2021Date of Patent: January 14, 2025Assignee: SINO-SWED TONGKANG BIO-TECH (SHENZHEN) LIMITEDInventors: Zuosheng Li, Hu Chen, Huijun Li, Li Dang, Liwen Liang, Cong Fang, Junye Tan, Ellen He, Sven Isac Skog, Ji Zhou
-
Patent number: 12195544Abstract: Provided herein are EGFR binding proteins and EGFR targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to EGFR. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such EGFR binding proteins, EGFR targeting trispecific proteins. Also disclosed are methods of using the disclosed EGFR binding proteins, EGFR targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.Type: GrantFiled: September 20, 2019Date of Patent: January 14, 2025Assignee: Harpoon Therapeutics, Inc.Inventors: Holger Wesche, Richard J. Austin
-
Patent number: 12180304Abstract: The present disclosure provides a variable region sequence of a broad-spectrum antibody against clothianidin and dinotefuran, where a gene encoding a heavy chain variable region has an amino acid sequence shown in SEQ ID NO: 2. The present disclosure further discloses a broad-spectrum intact recombinant antibody against clothianidin and dinotefuran, including a heavy chain constant region, a heavy chain variable region, a light chain constant region, and a light chain variable region, where a gene encoding the heavy chain variable region has an amino acid sequence shown in SEQ ID NO: 2. The sequence genes obtained by the present disclosure are ligated to an expression vector containing a heavy chain constant region gene and a light chain constant region gene, respectively, and an intact recombinant antibody is expressed and obtained by using mammalian cells with a double-plasmid system.Type: GrantFiled: July 28, 2021Date of Patent: December 31, 2024Assignee: Zhejiang UniversityInventors: Yirong Guo, Yunyun Chang, Ying Zhao, Pengyan Liu, Ying Liu, Yang Chen, Guonian Zhu
-
Patent number: 12161136Abstract: The presently disclosed subject matter relates to methods of screening raw materials and pet food products to manufacture a palatable pet food product. The presently disclosed subject matter also relates to methods for identifying compounds that modulate the activity and/or expression of a taste receptor.Type: GrantFiled: June 13, 2019Date of Patent: December 10, 2024Assignee: MARS, INCORPORATEDInventors: Scott Joseph McGrane, Matthew Ronald Gibbs, Boris Klebansky, Richard Masten Fine
-
Patent number: 12134656Abstract: Provided herein are methods and compositions relating to libraries of optimized antibodies having nucleic acids encoding for an antibody comprising modified sequences. Libraries described herein comprise nucleic acids encoding Dickkopf WNT signaling pathway inhibitor 1 (DKK1) antibodies. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.Type: GrantFiled: November 17, 2022Date of Patent: November 5, 2024Assignee: Twist Bioscience CorporationInventors: Aaron Sato, Tom Yuan, Linya Wang, Fumiko Axelrod
-
Patent number: 12122850Abstract: The present invention relates to GPC3×CD3 bispecific antibodies, GPC3×CD28 bispecific antibodies and the combination of two, agonistic and fully human KA-bodies with one targeting GPC3×CD3 and the other targeting GPC3×CD28, and both not competing for the binding to GPC3. The present invention also relates to the use of the bispecific antibodies for the treatment of GPC3 positive malignancies.Type: GrantFiled: March 14, 2023Date of Patent: October 22, 2024Assignee: LamKap Bio gamma AGInventors: Eric Hatterer, Anja Seckinger, Dirk Hose
-
Patent number: 12098200Abstract: Provided herein are single domain antibodies (sdAbs) configured for passing the blood brain barrier in a human or mammal brain. Methods of using such sdAbs are also described herein, such as methods of binding to brain cells, binding with and transporting other sdAbs with beneficial functionalities, binding to and transporting biochemical or pharmaceutical species with beneficial functionalities, and treating, diagnosing, or prophylactically treating a disease, malignancy, or condition.Type: GrantFiled: October 12, 2022Date of Patent: September 24, 2024Assignee: National Technology & Engineering Solutions of Sandia, LLCInventors: Brooke Nicole Harmon, Maxwell Stefan, Jennifer Schwedler, Christopher Sumner, Yooli Kim Light, Catherine Margaret Mageeney
-
Patent number: 12043668Abstract: An antibody, or an antigen-binding fragment thereof, that binds specifically to human CSF-1R includes a heavy chain variable domain that contains a HCDR1 region having the sequence of SEQ ID NO: 4, a HCDR2 region having the sequence of SEQ ID NO: 5, and a HCDR3 region having the sequence of SEQ ID NO: 6; and a light chain variable domain that contains a LCDR1 region having the sequence of SEQ ID NO: 7, a LCDR2 region having the sequence of SEQ ID NO: 8, and a LCDR3 region having the sequence of SEQ ID NO: 9. The heavy chain variable domain comprises the sequence of SEQ ID NO: 2, and wherein the light chain variable domain comprises the sequence of SEQ ID NO: 3.Type: GrantFiled: December 13, 2019Date of Patent: July 23, 2024Assignee: DEVELOPMENT CENTER FOR BIOTECHNOLOGYInventors: Chen-Hsuan Ho, Chu-Bin Liao, Yu-Kai Chen, Chen-Wei Huang, Tze-Ping Yang, Szu-Liang Lai
-
Patent number: 11976124Abstract: The present disclosure provides isolated monoclonal antibodies or an antigen-binding portion thereof that specifically bind to CD40 preferably human CD40 with high affinity, and that function as CD40 agonists. The disclosed invention also relates to antibodies that are chimeric, humanized, bispecific, derivatized, single chain antibodies or portions of fusion proteins. Nucleic acid molecules encoding the antibodies of the disclosed invention, hybridoma, and methods for expressing the antibodies of the disclosed invention are also provided. Pharmaceutical compositions comprising the antibodies of the disclosed invention are also provided. This disclosure also provides methods for regulating humoral and cellular immune responses, as well as methods for treating cancer using an anti-CD40 agonist antibody of the disclosed invention.Type: GrantFiled: December 23, 2020Date of Patent: May 7, 2024Assignee: ABVISION, INC.Inventors: Chang-Hsin Chen, Gloria Zhang, Guochen Yan, Cheng-Chi Chao